Celecoxib and Cyclophosphamide Combination

The combination of celecoxib and cyclophosphamide represents a therapeutic approach that has been investigated in clinical trials for various cancers. This combination pairs cyclophosphamide, a traditional chemotherapy agent, with celecoxib, a selective COX-2 inhibitor that has shown potential anti-angiogenic properties. ## Mechanism and Rationale The therapeutic rationale behind this combination involves multiple mechanisms: - Cyclophosphamide at low, continuous doses (often called "metronomic" dosing) has demonstrated anti-angiogenic activity in preclinical studies[1]. - Celecoxib, as a selective cyclooxygenase-2 (COX-2) inhibitor, also exhibits potent inhibition of angiogenesis[2]. - The combination aims to leverage these complementary anti-angiogenic effects while potentially reducing toxicity compared to conventional high-dose chemotherapy regimens. ## Clinical Trials and Applications Several phase I and II trials have evaluated this combination: - A phase II trial investigated continuous low-dose oral cyclophosphamide (50 mg daily) with celecoxib (400 mg twice daily) in patients with renal cell carcinoma (RCC)[1]. - Another study combined oral cyclophosphamide at 50 mg daily with escalating doses of celecoxib (100mg to 400mg twice daily) in patients with various advanced malignancies[2]. - A phase II study evaluated "high-dose" celecoxib (400 mg twice daily) with metronomic low-dose cyclophosphamide (50 mg daily) and methotrexate in patients with relapsed and refractory lymphoma[3]. ## Efficacy and Safety The clinical outcomes of these trials have shown: - In RCC patients, the combination showed limited activity with a disease control rate of 12.5%, including one partial response and three cases of stable disease for longer than 6 months[1]. - The median progression-free survival was 3.5 months and median overall survival was 14.5 months in the RCC trial[1]. - The combination was generally well-tolerated, with common toxicities including neutropenia, anemia, fatigue, and nausea[2]. - No excessive thrombotic, hemorrhagic, or cardiovascular complications related to celecoxib were observed in one trial[2]. ## Dosing Regimen The typical dosing regimen used in these trials was: - Cyclophosphamide: 50 mg orally daily - Celecoxib: 400 mg orally twice daily This combination represents an investigational approach that continues to be studied for its potential benefits in various cancer types, particularly where anti-angiogenic strategies may be beneficial.

Other names

Cyclophosphamide/CelecoxibCelecoxib/Cyclophosphamide